Literature DB >> 28228277

Prospects for a Zika Virus Vaccine.

Dan H Barouch1, Stephen J Thomas2, Nelson L Michael3.   

Abstract

A recent unprecedented outbreak of Zika virus (ZIKV) in the Americas has been associated with microcephaly and other congenital malformations in infants as well as Guillain-Barre syndrome in adults. The development of a safe and effective ZIKV vaccine is therefore an urgent global health priority. Promising data from preclinical vaccine studies in mice and monkeys suggest that an effective vaccine will likely be possible, but important scientific challenges remain. Here we review the current state of ZIKV vaccine development. We discuss different vaccination strategies and we highlight challenges facing clinical evaluation of ZIKV vaccine candidates.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28228277      PMCID： PMC5357134          DOI： 10.1016/j.immuni.2017.02.005

Source DB:  PubMed          Journal:  Immunity        ISSN： 1074-7613            Impact factor:   31.745


  74 in total

Review 1.  Neutralization and antibody-dependent enhancement of dengue viruses.

Authors:  Scott B Halstead
Journal:  Adv Virus Res       Date:  2003       Impact factor: 9.937

2.  Humoral immunity and correlation between ELISA, hemagglutination inhibition, and neutralization tests after vaccination against tick-borne encephalitis virus in children.

Authors:  Giulietta Venturi; Rosanna Mel; Antonella Marchi; Sebastiano Mancuso; Floriana Russino; Giusi Da Pra; Nunziato Papa; Gianni Bertiato; Cristiano Fiorentini; Maria Grazia Ciufolini
Journal:  J Virol Methods       Date:  2006-02-03       Impact factor: 2.014

3.  Immunological enhancement of dengue virus replication.

Authors:  S B Halstead; J S Chow; N J Marchette
Journal:  Nat New Biol       Date:  1973-05-02

Review 4.  Vaccines: correlates of vaccine-induced immunity.

Authors:  Stanley A Plotkin
Journal:  Clin Infect Dis       Date:  2008-08-01       Impact factor: 9.079

5.  Dengue Virus (DV) enhancing antibody activity in preillness plasma does not predict subsequent disease severity or viremia in secondary DV infection.

Authors:  Kamolwish Laoprasopwattana; Daniel H Libraty; Timothy P Endy; Ananda Nisalak; Supamit Chunsuttiwat; David W Vaughn; George Reed; Francis A Ennis; Alan L Rothman; Sharone Green
Journal:  J Infect Dis       Date:  2005-07-05       Impact factor: 5.226

6.  Efficacy of single-dose SA 14-14-2 vaccine against Japanese encephalitis: a case control study.

Authors:  M B Bista; M K Banerjee; S H Shin; J B Tandan; M H Kim; Y M Sohn; H C Ohrr; J L Tang; S B Halstead
Journal:  Lancet       Date:  2001-09-08       Impact factor: 79.321

7.  Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis.

Authors:  F Guirakhoo; Z X Zhang; T J Chambers; S Delagrave; J Arroyo; A D Barrett; T P Monath
Journal:  Virology       Date:  1999-05-10       Impact factor: 3.616

8.  Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity.

Authors:  D W Vaughn; S Green; S Kalayanarooj; B L Innis; S Nimmannitya; S Suntayakorn; T P Endy; B Raengsakulrach; A L Rothman; F A Ennis; A Nisalak
Journal:  J Infect Dis       Date:  2000-01       Impact factor: 5.226

9.  Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial.

Authors:  E Tauber; H Kollaritsch; M Korinek; P Rendi-Wagner; B Jilma; C Firbas; S Schranz; E Jong; A Klingler; S Dewasthaly; C S Klade
Journal:  Lancet       Date:  2007-12-01       Impact factor: 79.321

10.  Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2-3 September, 2004.

Authors:  Joachim Hombach; Tom Solomon; Ichiro Kurane; Julie Jacobson; David Wood
Journal:  Vaccine       Date:  2005-07-18       Impact factor: 3.641
View more
  44 in total

1.  Sustained maternal antibody and cellular immune responses in pregnant women infected with Zika virus and mother to infant transfer of Zika-specific antibodies.

Authors:  Ai-Ris Y Collier; Erica N Borducchi; Abishek Chandrashekar; Edward Moseley; Lauren Peter; Nicholas S Teodoro; Joseph Nkolola; Peter Abbink; Dan H Barouch
Journal:  Am J Reprod Immunol       Date:  2020-07-01       Impact factor: 3.886

2.  Characterization of two engineered dimeric Zika virus envelope proteins as immunogens for neutralizing antibody selection and vaccine design.

Authors:  Chunpeng Yang; Fang Zeng; Xinyu Gao; Shaojuan Zhao; Xuan Li; Sheng Liu; Na Li; Chenglin Deng; Bo Zhang; Rui Gong
Journal:  J Biol Chem       Date:  2019-05-28       Impact factor: 5.157

Review 3.  Therapeutic Approaches for Zika Virus Infection of the Nervous System.

Authors:  Rachel P M Abrams; Jamie Solis; Avindra Nath
Journal:  Neurotherapeutics       Date:  2017-10       Impact factor: 7.620

4.  A new class of broadly neutralizing antibodies that target the glycan loop of Zika virus envelope protein.

Authors:  Panke Qu; Chao Zhang; Min Li; Weimin Ma; Pei Xiong; Qingwei Liu; Gang Zou; Dimitri Lavillette; Feifei Yin; Xia Jin; Zhong Huang
Journal:  Cell Discov       Date:  2020-02-04       Impact factor: 10.849

Review 5.  Zika virus infection of first-trimester human placentas: utility of an explant model of replication to evaluate correlates of immune protection ex vivo.

Authors:  Matthew Petitt; Takako Tabata; Henry Puerta-Guardo; Eva Harris; Lenore Pereira
Journal:  Curr Opin Virol       Date:  2017-12       Impact factor: 7.090

6.  Zika Virus: Relevance to the State of Hawai'i.

Authors:  William J Lew; Wen-Yang Tsai; Venkataraman Balaraman; Kore Kai Liow; Jasmine Tyson; Wei-Kung Wang
Journal:  Hawaii J Med Public Health       Date:  2019-04

7.  Durability and correlates of vaccine protection against Zika virus in rhesus monkeys.

Authors:  Peter Abbink; Rafael A Larocca; Kittipos Visitsunthorn; Michael Boyd; Rafael A De La Barrera; Gregory D Gromowski; Marinela Kirilova; Rebecca Peterson; Zhenfeng Li; Ovini Nanayakkara; Ramya Nityanandam; Noe B Mercado; Erica N Borducchi; Abishek Chandrashekar; David Jetton; Shanell Mojta; Priya Gandhi; Jake LeSuer; Shreeya Khatiwada; Mark G Lewis; Kayvon Modjarrad; Richard G Jarman; Kenneth H Eckels; Stephen J Thomas; Nelson L Michael; Dan H Barouch
Journal:  Sci Transl Med       Date:  2017-12-13       Impact factor: 17.956

Review 8.  Zika in the Americas, year 2: What have we learned? What gaps remain? A report from the Global Virus Network.

Authors:  Matthew T Aliota; Leda Bassit; Shelton S Bradrick; Bryan Cox; Mariano A Garcia-Blanco; Christina Gavegnano; Thomas C Friedrich; Thaddeus G Golos; Diane E Griffin; Andrew D Haddow; Esper G Kallas; Uriel Kitron; Marc Lecuit; Diogo M Magnani; Caroline Marrs; Natalia Mercer; Edward McSweegan; Lisa F P Ng; David H O'Connor; Jorge E Osorio; Guilherme S Ribeiro; Michael Ricciardi; Shannan L Rossi; George Saade; Raymond F Schinazi; Geraldine O Schott-Lerner; Chao Shan; Pei-Yong Shi; David I Watkins; Nikos Vasilakis; Scott C Weaver
Journal:  Antiviral Res       Date:  2017-06-06       Impact factor: 5.970

Review 9.  Mathematical modeling of within-host Zika virus dynamics.

Authors:  Katharine Best; Alan S Perelson
Journal:  Immunol Rev       Date:  2018-09       Impact factor: 12.988

10.  U.S. pregnant women's knowledge and attitudes about behavioral strategies and vaccines to prevent Zika acquisition.

Authors:  Lauren Dapena Fraiz; Ariel de Roche; Christine Mauro; Marina Catallozzi; Gregory D Zimet; Gilla K Shapiro; Susan L Rosenthal
Journal:  Vaccine       Date:  2017-11-20       Impact factor: 3.641
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.